Form 4: Timothy A. Springer Reports Stock Purchases in Cartesian Therapeutics, Inc.

Director and 10% owner Timothy A. Springer reports purchasing additional shares of Cartesian Therapeutics, Inc. (RNAC) common stock.

Summary

• On January 13, 2025, Timothy A. Springer purchased 7,962 shares of Cartesian Therapeutics, Inc. (RNAC) common stock at a weighted average price of $16.8576 per share.
• The prices for these shares ranged from $16.40 to $17.3124.
• On the same day, Springer also purchased 8,983 shares at a weighted average price of $17.7822 per share, with prices ranging from $17.40 to $18.00.
• On January 14, 2025, Springer purchased an additional 4,022 shares at $18 per share.
• Following these transactions, Springer directly owns 8,531,462 shares of common stock.
• Springer also indirectly owns 330,695 shares through his wife and 529,798 shares through TAS Partners LLC, where he is the managing member.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally seen as a positive sign, but without more context, it's difficult to gauge the significance.

Positives

• The director's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders.

Stakeholder Impact

• The stock purchases by a director and significant shareholder could potentially increase investor confidence.

Key Dates